Starpharma Holdings Limited is a world leader in the development of nanotechnology products for pharmaceutical, life-science and other applications.

Starpharma’s lead product is VivaGel^®, a gel-based formulation of a nano-pharmaceutical under development as a vaginal microbicide to prevent the transmission of sexually transmitted infections, including HIV and genital herpes.

VivaGel^® is at the expanded safety/Phase IIa stage of clinical development. VivaGel^® has been granted Fast Track status by the US Food and Drug Administration (FDA), which will accelerate the clinical and regulatory process. In addition, VivaGel^® has been awarded US$20.3 million by the National Institutes of Health (NIH) to progress the development for HIV. The NIH has provided additional funding to develop VivaGel^® against genital herpes.

Starpharma has a 100% owned US-based subsidiary Dendritic Nanotechnologies Inc (DNT) expanding the company’s potential products to include drug delivery and industrial specialty chemical applications, many of which have near-term cash-flow opportunities.